SB
Spine BioPharma, Inc.
SEC filingPharmaceuticals · New York, NY
Amount raised$385Ksold at filing
Total offering$8.5M$8.1M still open
Investors in the raise3count reported to the SEC
FiledJun 5, 2026first sale May 22, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Fran R. MageeExecutive Officer
John J. ViscogliosiDirector
Thomas R. Bumol, PhDDirector
Marc R. ViscogliosiExecutive Officer, Director
Frank R. Cammisa, MDDirector
Executive officers, directors and promoters as listed on the Form D.